Clear Street Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

August 31, 2026 1:05 PM

Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $173.00 price target on Protagonist Therapeutics (NASDAQ: PTGX)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found